Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Депрессия при шизофрении: подходы к терапии

Список литературы

  1. Андрусенко М. П., Морозова М. А. Комбинированное использование антидепрессантов и нейролептиков при аффективных расстройствах и шизофрении: показания к назначению, побочные эффекты и осложнения. Психиатрия и психофармакотерапия. 2001; 36(1): 4–9.
  2. Бубнова Ю. С., Дорофейков В. В., Мазо Г. Э. и др. К вопросу о механизмах развития депрессии при шизофрении. Психиатрия и психофармакотерапия им. П. Б. Ганнушкина. 2012; 14(4): 21–26.
  3. Бутома Б. Г., Мазо Г. Э., Дубинина Е. Е. и соавт. Роль иммунного воспаления в механизмах формирования депрессии при шизофрении. Психическое здоровье. 2016; 10: 36–49.
  4. Горобец Л. Н., Мазо Г. Э. Гиперпролактинемия при использовании антипсихотиков второго поколения: принципы профилактики, диагностики и коррекции. Обозрение психиатрии и медицинской психологии им. В. М. Бехтерева. 2017; 1: 63–69.
  5. Мазо Г. Э. Влияние терапии сероквелем на депрессивную симптоматику в структуре шизофрении. Психиатрия и психофармакотерапия. 2003; 5(6): 259–262.
  6. Мазо Г. Э. Депрессия как осевой симптом шизофрении. Сибирский вестник психиатрии и наркологии. 2005; 36(2): 23–26.
  7. Мазо Г. Э. Влияние депрессии на течение шизофрении. Психиатрия и Психофармакотерапия. 2006; 3: 22–24.
  8. Мазо Г. Э., Горобец Л. Н. Замена антипсихотика как метод предотвращения формирования резистентности при шизофрении. Обозрение психиатрии и медицинской психологии им. В. М. Бехтерева. 2017; 3: 74–78.
  9. Мазо Г. Э., Горбачев С. Е. Депрессия при шизофрении: опыт и подходы практических врачей к диагностике и терапии. Социальная и клиническая психиатрия. 2009; 19(4): 5–15.
  10. Мазо Г. Э., Иванов М. В., Горбачев С. Е. Место современных антидепрессантов в лечении шизофрении: актуальный взгляд на проблему. Психиатрия и Психофармакотерапия. 2007; 9(6): 30–33.
  11. Мазо Г. Э., Кибитов А. О. Риск-менеджмент метаболических нарушений при использовании антипсихотиков. Обозрение психиатрии и медицинской психологии им. В. М. Бехтерева. 2016; 3: 98–102.
  12. Мазо Г. Э., Никифорова Ю. С., Щедрина Л. В. Влияние депрессии при шизофрении на уровень BDNF. Психиатрия и Психофармакотерапия им. П. Б. Ганнушкина. 2015; 17(1): 12–17.
  13. Маслеников Н. В., Цукарзи Э. Э., Мосолов С. Н. Депрессии при шизофрении: оценка когнитивных функций в динамике при лечении транскраниальной магнитной стимуляцией. Социальная и клиническая психиатрия. 2013; 23(1): 5–11.
  14. Мосолов С. Н., Кортезе Л., Брессан Р. А. и соавт. Лечение шизофрении: клинический опыт применения азенапина. Социальная и клиническая психиатрия. 2013; 2: 61–66.
  15. Смулевич А. Б., Дубицкая Э. Б. Транснозологическая ритмологическая модель депрессий (к проблеме систематики аффективных расстройств). Психиатр. и психофармакотер. 2013; 15: 5.
  16. Ajmal A., Joffe H., Nachtigall L. B. Psychotropic-induced hyperprolactinemia: a clinical review. Psychosomatics. 2014; 55(1): 29–36.
  17. Al-Hakeim H.K., Al-Rammahi D.A., Al-Dujaili A.H. IL-6, IL-18, sIL-2r, and TNF proinflammatory markers in depressed and patients with schizophrenia patients who are free of overt inflammation. J. Affect. Disord. 2015; 182: 106–14.
  18. Anderson G., Maes M., Berk M. Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2013; 42: 101–114.
  19. Anticevic A., Schleifer C., Youngsun T. C. Emotional and cognitive dysregulation in schizophrenia and depression: understanding common and distinct behavioral and neural mechanisms. Dialogues in Clinical Neuroscience. 2015; 17(4): 421–434.
  20. Benros M. E., Nielsen P. R., Nordentoft M. et al. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am. J. Psychiatry. 2011; 168(12): 1303–1310.
  21. Bortnick B., El-Khalili N., Banov M., Adson D., Datto C., et al. Efficacy and tolerability of extended release quetiapinefumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J. Affect Disord. 2011; 128: 83–94.
  22. Castle D. J., Slott Jensen J. K. Management of depressive symptoms in schizophrenia. Clin. Schizophr. Relat. Psychoses. 2015; 9(1): 13–20.
  23. Chaichan W. Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia. Psychiatry Clin. Neurosci. 2004; 58(4): 364–368.
  24. Citrome L. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Adv. Therap. 2013; 30(2): 114–126.
  25. Citrome L., Cucchiaro J., Sarma K., Phillips D., Silva R., Tsuchiya S. et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int. Clin. Psychopharmacol. 2012; 27: 165–176.
  26. Citrome L., Ketter T. A., Cucchiaro J., Loebel A. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J. Affect Disord. 2014; 155: 20–27.
  27. Cucchiaro J., Potkin S., Ogasa M., Loebel A. A double-blind comparaison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr. Bull. 2009; 35(1): 342–343.
  28. Duman R. S., Li N., Liu R. J. et al. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology. 2012; 62: 35–41.
  29. Ganzinelli S., Borda E., Sterin-Borda L. Autoantibodies from schizophrenia patients induce cerebral cox1/iNOS mRNA expression with NO/PGE2/MMP‐3 production. Int. J. Neuropsychopharmacol. 2010; 13(3): 293–303.
  30. Gohar S. M., Dieset I., Steen N. E. et al. Association between serum lipid levels, osteoprotegerin and depressive symptomatology in psychotic disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2018; May 2: Epub ahead of print.
  31. Gregory A., Mallikarjun P., Upthegrove R. Treatment of depression in schizophrenia: Systematic review and meta-analysis. The British Journal of Psychiatry. 2017; 211(4): 198–204.
  32. van der Heiden W., Könnecke R., Maurer K. et al. Depression in the long-term course of schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2005; 255(3): 174–184.
  33. Helfer B., Samara M. T., Huhn M. et al. Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis. Am. J. Psychiatry. 2016; 173(9): 876–886.
  34. Heo J. Y., Jeon H. J., Fava M et al. Efficacy of ziprasidone monotherapy in patients with anxious depression: A 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial. Journal of Psychiatric Research. 62: 56–61.
  35. Javitt D. C. Glutamatergic theories of schizophrenia. Isr. J. Psychiatry Relat. Sci. 2010; 47: 4–16.
  36. Jeon H. J., Fava M., Mischoulon D. et al. Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: a 12-week, randomized, double-blind, placebocontrolled, sequential parallel comparison trial. Int. Clin. Psychopharmacol. 2014; 29: 332e8.
  37. Kim S. W., Shin I. S., Kim J. M. et al. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia. Clin. Neuropharmacol. 2010; 33(3): 121–125.
  38. Kucerova J., Babinska Z., Horska K. et al. The common pathophysiology underlying the metabolic syndrome, schizophrenia and depression. A review. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech Repub. 2015; 159(2): 208–214.
  39. Kuromitsu J., Yokoi A., Kawai T. et al. Reduced neuropeptide Y mRNA levels in the frontal cortex of people with schizophrenia and bipolar disorder. Brain Res. Gene. Expr. Patterns. 2001; 1: 17–21.
  40. Lako I. M., Bruggeman R., Knegtering H. et al. A systematic review of instruments to measure depressive symptoms in patients with schizophrenia. J. Affect. Disord. 2012; 140: 38–47.
  41. Leucht S. Amisulpride — A selective dopamine antagonist and atypical antipsychotic: Results of a meta-analysis of randomized controlled trials. Int. J. Neuropsychopharmacol. 2004; 7(1): 15–20.
  42. Li X. L., Aou S., Oomura Y. et al. Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents. Neuroscience. 2002; 113: 607–615.
  43. Loebel A., Cucchiaro J., Xu J., Sarma K., Pikalov A., Kane J. M. Effectiveness of lurasidone v. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res. 2013; 147: 95–102.
  44. Maes M., Kubera M., Obuchowiczwa E. et al. Depression’s multiple comorbidities explained by (neuro) inflammatory and oxidative & nitrosative stress pathways. Neuro. Endocrinol. Lett. 2011; 32(1): 7–24.
  45. Maes M., Mihaylova I., Kubera M. et al. IgM-mediated autoimmune responses directed against multiple neoepitopes in depression: new pathways that underpin the inflammatory and neuroprogressive pathophysiology. J. Affect. Disord. 2011; 135(1–3): 414–418.
  46. Mauri M. C. et al. Antidepressant efficacy of the Antipsychotic Quetiapin: Pharmacodynamics and Clinical Data. Dual. Diagn. Open. Acc. 2016; 1: 21.
  47. Merritt K., McGuire P., Egerton A. Relationship between glutamate dysfunction and symptoms and cognitive functionin psychosis. Front. Psychiatry. 2013; 4: 151.
  48. Miller A. H., Raison C. L. Are Anti-inflammatory Therapies Viable Treatments for Psychiatric Disorders?: Where the Rubber Meets the Road. JAMA Psychiatry. 72(6): 527–528.
  49. Mortimer А. М. Update on the management of symptoms in schizophrenia: focus on amisulpride. Neuropsychiatric Disease and Treatment. 2009; 5: 267–277.
  50. Nakajima S., Takeuchi H., Fervaha G. et al. Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: Analysis of the CATIE Phase 2E data. Schizophrenia research. 2015; 161: 429–433.
  51. Németh G., Laszlovszky I., Czobor P., et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017; 389: 1103–1113.
  52. Ohmori H., Kanayama N. Immunogenicity of an inflammation‐associated product, tyrosine nitrated self-proteins. Autoimmun. Rev. 2005; 4(4): 224–229.
  53. Papakostas G. I., Fava M., Baer L. et al. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results from a Randomized, Double-Blind, Placebo-Controlled Study. The American journal of psychiatry. 2015; 172(12): 1251–1258.
  54. Papp M., Gruca P., Lasoń-Tyburkiewicz M., et al. Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression. Behav. Pharmacol. 2014; 25: 567–574.
  55. Peuskens J., Moller H., Puech A. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. Eur. Neuropsychopharmacol. 2002; 12(4): 305–310.
  56. Peuskens J., Pani L., Detraux J. et al. The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review. CNS Drugs. 2014; 28(5): 421–453.
  57. Peuskens J., Van Baelen B., De Smedt C., Lemmens P. Effects of risperidone on affective symptoms in patients with schizophrenia. International Clinical Psychopharmacalogy. 2000; 15(6): 343–349.
  58. Potkin S. G., Thyrum P. T., Alva G. et al. Pharmacokinetic Study Group. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. J. Clin. Psychopharmacol. 2002; 22(2): 174–82.
  59. Roberts R. J., Findlay L. J., El-Mallakh P. L., El-Mallakh R. Update on schizophrenia and bipolar disorder: focus on cariprazine. Neuropsychiatric Disease and Treatment. 2016; 12: 1837–1842.
  60. Rummel-Kluge C., Komossa K., Schwarz S. et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis. Schizophr. Res. 2010. 123(2–3): 225–233.
  61. Rybakowski J. K., Vansteelandt K., Szafranski T. et al. Treatment of depression in first episode of schizophrenia: Results from EUFEST. European Neuropsychopharmacology. 2012; 22(12): 875–882.
  62. Samsom J. N., Wong A. H. Schizophrenia and Depression Co-Morbidity: What We have Learned from Animal Models. Frontiers in Psychiatry. 2015; 6: 13.
  63. Siris S. G. Depression in schizophrenia: perspectives in the era of «atypical» antipsychotic agents. Am. J. Psychiatry. 2000; 157: 1379–1389.
  64. Stadlbauer U., Langhans W., Meyer U. Administration of the Y2 receptor agonist PYY3–36 in mice induces multiple behavioral changes relevant to schizophrenia. Neuropsychopharmacology. 2013; 38: 2446–2455.
  65. Stahl S. M., Laredo S., Morrissette D. A. Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data. Ther. Adv. Psychopharmacol. 2020; 10: 2045125320905752.
  66. Taylor D., Paton C., Kapur S. The Maudsley Prescribing Guidelines. 10th Edition. London: Informa Healthcare, 2009.
  67. Tollefson G. D., Sanger T. M., Lu Y. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch. Gen. Psychiatry. 1998; 55: 250–258.
  68. Umemori J., Takao K., Koshimizu H. et al. ENU-mutagenesis mice with a non-synonymous mutation in Grin1 exhibit abnormal anxiety-like behaviors, impaired fear memory, and decreased acoustic startle response. BMC ResNotes. 2013; 6: 203.
  69. Upthegrove R., Marwaha S., Birchwood M. Depression and Schizophrenia: Cause, Consequence, or Trans-diagnostic Issue? Schizophr. Bull. 2017; 43(2): 240–244.
  70. Vanelle J-M, Douki S. A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. Eur. Psychiatry. 2006; 21(8): 523–530.
  71. Zanardi R., Smeraldi E. A double-blind, randomised, controlled cаlinical trial of acetyl-l- carnitine vs. amisulpride in the treatment of dysthymia. Eur. Neuropsychopharmacol. 2006; 16(4): 281–287.
  72. Zhao T., Park T. W., Yang J. C. et al. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: An 8-week, open-label, multicenter trial. Int. Clin. Psychopharmacol. 2012; 27: 184–190.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*